5 Stocks Stealing The Show

4. Tempus AI Inc. (NASDAQ:TEM)

Tempus AI extended its winning streak to a 3rd straight session on Wednesday, surging 13.89 percent to close at $56.41 apiece, as investors took heart from the official launch of a new test kit capable of detecting cancer from a blood sample alone.

In an updated report, Tempus AI Inc. (NASDAQ:TEM) said that it partnered with Predicta Biosciences—a precision oncology company—for the launch of the GenoPredicta test kit, which can extract deep insights from a blood sample or bone marrow with as few as 50 cancer cells.

Tempus AI Inc. (NASDAQ:TEM) said that the test kit is so sensitive that it can track cancer even in individuals who previously did not have enough detectable cancer cells for analysis.

The test kit would support medical practitioners and researchers in the accurate diagnosis of cancer, in figuring out how severe the disease is, identifying if drugs or therapies work, and tracking for cancer cells left after treatment.

“GenoPredicta offers a novel, unified solution for our life science partners and a comprehensive replacement for traditional, siloed testing,” Tempus AI Inc. (NASDAQ:TEM) Chief Scientific Officer Kate Sasser said.

“By consolidating flow cytometry, cytogenetics, and WGS into one ultrasensitive workflow, we can identify high-risk biomarkers and track clonal evolution from as few as 50 tumor cells. Crucially, because the assay delivers 100 percent concordance between peripheral blood and bone marrow, it can provide these deep insights while sparing patients from biopsies,” she noted.